MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

Search

Anavex Life Sciences Corp

Geschlossen

BrancheGesundheitswesen

9.57 -0.1

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.36

Max

9.66

Schlüsselkennzahlen

By Trading Economics

Einkommen

-491K

-12M

EPS

-0.14

Angestellte

42

EBITDA

-1.8M

-14M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+197.49% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

8. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

745M

Vorheriger Eröffnungskurs

9.67

Vorheriger Schlusskurs

9.57

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Anavex Life Sciences Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. Apr. 2025, 23:27 UTC

Top News

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- 2nd Update

28. Apr. 2025, 23:07 UTC

Top News

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- Update

28. Apr. 2025, 23:03 UTC

Ergebnisse

Waste Management 1Q Profit Falls, Revenue Misses Estimates

28. Apr. 2025, 23:47 UTC

Market Talk

Gold Edges Lower as Traders Assess Mixed Signals From Treasury Secretary Bessent -- Market Talk

28. Apr. 2025, 23:17 UTC

Ergebnisse

Jiangxi Copper 1Q Rev CNY111.61B Vs. CNY122.52B >0358.HK

28. Apr. 2025, 23:17 UTC

Ergebnisse

Jiangxi Copper 1Q Net CNY1.95B Vs. Net CNY1.71B >0358.HK

28. Apr. 2025, 23:13 UTC

Ergebnisse

China Merchants Securities: Higher Interest Income, Fee Income Also Aided 1Q Results>600999.SH

28. Apr. 2025, 23:13 UTC

Ergebnisse

China Merchants Securities 1Q Rev CNY4.71B Vs. CNY4.30B >600999.SH

28. Apr. 2025, 23:13 UTC

Ergebnisse

China Merchants Securities: Gains From Investments in Financial Instruments Supported Results >600999.SH

28. Apr. 2025, 23:13 UTC

Ergebnisse

China Merchants Securities 1Q Net CNY2.31B Vs. Net CNY2.16B >600999.SH

28. Apr. 2025, 23:08 UTC

Ergebnisse

China Longyuan Power: 1Q Power Generation Declined 4.42% on Year>0916.HK

28. Apr. 2025, 23:08 UTC

Ergebnisse

China Longyuan Power 1H Rev CNY8.14B Vs. CNY8.07B >0916.HK

28. Apr. 2025, 23:08 UTC

Ergebnisse

China Longyuan Power 1H Net CNY1.98B Vs. Net CNY2.53B >0916.HK

28. Apr. 2025, 23:04 UTC

Ergebnisse

Huaneng Power: 1Q Net Was Mainly Driven By Decline in Domestic Fuel Costs >0902.HK

28. Apr. 2025, 23:04 UTC

Ergebnisse

Huaneng Power: Decrease in Electricity Tariffs Weighed on Rev >0902.HK

28. Apr. 2025, 23:04 UTC

Ergebnisse

Huaneng Power 1Q Rev CNY60.33B ; Down 7.7% on Year>0902.HK

28. Apr. 2025, 23:04 UTC

Ergebnisse

Huaneng Power 1Q Net CNY4.97B; up 8.2% on Year >0902.HK

28. Apr. 2025, 23:00 UTC

Ergebnisse

Jiangsu Expressway 1Q Rev CNY4.78B Vs. CNY3.47B >0177.HK

28. Apr. 2025, 23:00 UTC

Ergebnisse

Jiangsu Expressway: 1Q Rev Rose Due to Increase in Road Construction Projects >0177.HK

28. Apr. 2025, 23:00 UTC

Ergebnisse

Jiangsu Expressway: Decline in Investment Income, Fall in Revenue Post Asset Disposal Weighed on 1Q Net >0177.HK

28. Apr. 2025, 23:00 UTC

Ergebnisse

Jiangsu Expressway 1Q Net CNY1.21B Vs. Net CNY1.25B >0177.HK

28. Apr. 2025, 22:57 UTC

Top News

Trump Signs Order Requiring Nationwide List of Sanctuary Cities and States -- 8th Update

28. Apr. 2025, 22:55 UTC

Ergebnisse

Tsingtao Brewery: Higher Sales Volumes of Beer Supported Results >0168.HK

28. Apr. 2025, 22:55 UTC

Ergebnisse

Tsingtao Brewery 1Q Net CNY1.71B Vs. Net CNY1.60B >0168.HK

28. Apr. 2025, 22:55 UTC

Ergebnisse

Tsingtao Brewery 1Q Rev CNY10.45B Vs. CNY10.15B >0168.HK

28. Apr. 2025, 22:52 UTC

Ergebnisse

S.F. Holding: Results Supported by Higher Contributions From Logistics Business >002352.SZ

28. Apr. 2025, 22:52 UTC

Ergebnisse

S.F. Holding 1Q Net CNY2.23B Vs. Net CNY1.91B >002352.SZ

28. Apr. 2025, 22:52 UTC

Ergebnisse

S.F. Holding: Cost Controls Also aided 1Q Results >002352.SZ

28. Apr. 2025, 22:52 UTC

Ergebnisse

S.F. Holding 1Q Rev CNY69.85B Vs. CNY65.34B >002352.SZ

28. Apr. 2025, 22:46 UTC

Ergebnisse

Shandong Gold Mining: Increase in Selling Price of Gold Supported Results>600547.SH

Peer-Vergleich

Kursveränderung

Anavex Life Sciences Corp Prognose

Kursziel

By TipRanks

197.49% Vorteil

12-Monats-Prognose

Durchschnitt 28.5 USD  197.49%

Hoch 42 USD

Tief 15 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Anavex Life Sciences Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

9.31 / 9.655Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Weak Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.